ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-09-01 05:21Company Overview - Anke Bioengineering (Group) Co., Ltd. is located in Hefei, Anhui Province, established on September 28, 2000, and listed on October 30, 2009. The company specializes in research, development, production, and sales of biotechnological products, including cell engineering, gene engineering, gene testing, and precision medicine [1]. Financial Performance - On September 1, Anke Bio's stock rose by 5.44%, reaching a price of 11.83 CNY per share, with a trading volume of 508 million CNY and a turnover rate of 3.62%. The total market capitalization is 19.786 billion CNY [1]. - The main revenue composition of Anke Bio includes 88.24% from gene engineering drugs, 11.67% from external patches, and 0.09% from other supplementary products [1]. Shareholder Information - Southern Fund's Southern CSI 1000 ETF (512100) entered the top ten circulating shareholders of Anke Bio in the second quarter, holding 10.7976 million shares, which accounts for 0.88% of the circulating shares. The estimated floating profit today is approximately 6.5866 million CNY [2]. - The Southern CSI 1000 ETF was established on September 29, 2016, with a latest scale of 64.953 billion CNY. Year-to-date returns are 26.15%, ranking 1602 out of 4223 in its category, while the one-year return is 65.35%, ranking 1153 out of 3780 [2]. Fund Management - The fund manager of Southern CSI 1000 ETF is Cui Lei, who has been in the position for 6 years and 300 days. The total asset scale under management is 94.976 billion CNY, with the best fund return during the tenure being 133.3% and the worst being -18.12% [3].